E-courses - UROONCO Prostate Cancer

The European School of Urology provides up-to-date information for urologists and residents worldwide.

E-courses are developed by urologists from all over Europe, supported by the e-learning specialists of the EAU and in line with the EAU Clinical Guidelines, delivering high standard, up-to-date courses.

EAU Education Online e-Platform is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide CME activity for medical specialists.

For infomation please visit EAU E-courses page.

The following E-courses are available at EAU website.

*NEW Advanced Prostate Cancer – Non-Metastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis, and treatments of prostate cancer. This course series contains five courses, each of them addresses an important topic in diagnosis, treatment, and management of prostate cancer. Each course is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 1 to 3 European CME credits (ECMEC). The five courses are:

Course 1: Basis of ADT (published in March 2020)
Course 2: Hormone-sensitive nmPCa
Course 3: Metastatic hormone-sensitive PCa (published in June 2020)
Course 4: Non-metastatic CRPC (published in November 2020)
Course 5: Metastatic CRPC (published in Jan 2021 )

The development of this course has been supported by Jansen with a concession of an unrestricted educational grant.

Learning Objectives

Definition of Hormone sensitive nmPCa / nmPCa / MPCa / CRPC and classification
Information about diagnostic tools, how to combine them and the value of their results
Information on prognosis factors, predictive factors and patient stratification
Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

Chapter 1: ADT and radiotherapy
Chapter 2: ADT monotherapy
Chapter 3: ADT and surgery

At a glance

Publication date: March 2022
Duration: 120 minutes approximately
CME: 2 European CME credits (ECMEC)

Start learning now

Advanced Prostate Cancer – Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis, and treatments of prostate cancer. This course is the fourth part of the course series.

Course 1: Basis of ADT (published in March 2020)
Course 2: Hormone-sensitive nmPCa (published in March 2022)
Course 3: Metastatic hormone-sensitive PCa (published in June 2020)
Course 4: Non-metastatic CRPC (published in November 2020)
Course 5: Metastatic CRPC

The development of this course has been supported by Jansen with a concession of an unrestricted educational grant.

Learning Objectives

Definition of Hormone sensitive nmPCa / nmPCa / MPCa / CRPC and classification
Information about diagnostic tools, how to combine them and the value of their results
Information on prognosis factors, predictive factors and patient stratification
Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

Chapter 1: Definition
Chapter 2: Biological mechanisms
Chapter 3: Disease heterogeneity
Chapter 4: First-line treatment
Chapter 5: Follow-up and progression
Chapter 6: Second- and further lines
Chapter 7: Potential future: biomarkers / drugs

At a glance

Publication date: January 2021
Duration: 150 – 180 minutes approximately
CME: 3 European CME credits (ECMEC)

Start learning now

Advanced Prostate Cancer – Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis, and treatments of prostate cancer. This course is the fourth part of the course series.

Course 1: Basis of ADT (published in March 2020)
Course 2: Hormone-sensitive nmPCa (published in March 2022)
Course 3: Metastatic hormone-sensitive PCa (published in June 2020)
Course 4: Non-metastatic CRPC
Course 5: Metastatic CRPC (published in Jan 2021 )

The development of this course has been supported by Jansen with a concession of an unrestricted educational grant.

Learning Objectives

Definition of Hormone sensitive nmPCa / nmPCa / MPCa / CRPC and classification
Information about diagnostic tools, how to combine them and the value of their results
Information on prognosis factors, predictive factors and patient stratification
Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

Chapter 1: Definition and Occurrence
Chapter 2: Clarifying metastasis and progression
Chapter 3: Predicting outcomes: the role of PSA-DT
Chapter 4: Treatment

At a glance

Publication date: November 2020
Duration: 60-90 minutes approximately
CME: 1 European CME credits (ECMEC)

Start learning now

Advanced Prostate Cancer – Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis and treatments of prostate cancer. The five courses are:

Course 1: Basis of ADT
Course 2: Hormone-sensitive nmPCa
Course 3: Metastatic hormone-sensitive PCa
Course 4: Non-metastatic CRPC
Course 5: Metastatic CRPC

The development of this course has been supported by Jansen with a concession of an unrestricted educational grant.

Learning Objectives

Definition of Hormone-sensitive nmPCa / nmPCa / MPCa / CRPC and classification
Information about diagnostic tools, how to combine them and the value of their results
Information on prognosis factors, predictive factors and patient stratification
Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

Chapter 1: Definition and classification
Chapter 2: Clinical evaluation
Chapter 3: Treatment
Chapter 4: Follow-up and surveillance strategies

At a glance

Duration: 90 minutes per course approximately
CME: 1 European CME credits (ECMEC)

Start learning now

Advanced Prostate Cancer – Basis of Androgen Deprivation Therapy

This course series Advanced Prostate Cancer gives clinicians a complete view on clinical aspects, diagnosis and treatments of prostate cancer. The five courses are:

Course 1: Basis of ADT
Course 2: Hormone-sensitive nmPCa
Course 3: Metastatic hormone-sensitive PCa
Course 4: Non-metastatic CRPC
Course 5: Metastatic CRPC

This course Basis of Androgen Deprivation Therapy is the first part of the course series.

This course is supported by an independent educational grant from Janssen, the Pharmaceutical Companies of Johnson & Johnson.

Learning Objectives

Definition of Hormone-sensitive nmPCa / nmPCa / MPCa / CRPC and classification
Information about diagnostic tools, how to combine them and the value of their results
Information on prognosis factors, predictive factors and patient stratification
Information about treatment options, how to combine them, their differences and side-effects, when to progress to the next treatment stage, and how to evaluate these
Information on sound clinical decision making for patients with nmPCa, MPCa, Metastatic CRPC, and nmCRPC
Evaluation of learners’ knowledge about treatment of nmPCa, MPCa, Metastatic CRPC, and nmCRPC and their ability to apply this knowledge in devising care pathways for patients

Chapters

Chapter 1: Androgen Bio-synthesis
Chapter 2: Androgen Deprivation Therapy (ADT)
Chapter 3: Adverse Events and Side Effects

At a glance

Duration: 90 minutes per course approximately
CME: 1 European CME credits (ECMEC)

Start learning now

EAU Guidelines on Prostate Cancer

This course compiles the most recent clinical guidelines edited by the EAU on Prostate Cancer (PCa). The PCa guidelines course is divided into 4 learning modules.

Learning Objectives

Review the most updated EAU guidelines on Prostate Cancer
Learn how to make informed decisions in the treatment of Prostate Cancer Patients
Test your knowledge on the latest developments in Prostate Cancer according to the EAU Guidelines

At a glance

Duration: Approx. 180 minutes
CME: 3 European CME credits (ECMEC)

Start learning now